High cure rates of Helicobacter pylori infection using tripotassium dicitrato bismuthate, furazolidone and clarithromycin triple therapy for 1 week

Alimentary Pharmacology and Therapeutics

Volumn 13, Issue 3, 1999, Pages 311-315

  Xiao, S D ^a   Liu, W Z ^a   Hu, P J ^c   Xia, D H ^c   Tytgat, G N J ^b  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

^c Shanghai Inst of Digestive Disease ^*

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; BISMUTH CITRATE; CLARITHROMYCIN; FURAZOLIDONE; JOSAMYCIN; UREASE; ANTIINFECTIVE AGENT; ANTIULCER AGENT; ORGANOMETALLIC COMPOUND; PROTON PUMP; TOPICAL ANTIINFECTIVE AGENT;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DROWSINESS; DRUG EFFICACY; DYSPEPSIA; FEMALE; GRAM NEGATIVE INFECTION; HELICOBACTER PYLORI; HUMAN; MAJOR CLINICAL STUDY; MALE; NAUSEA; ORAL DRUG ADMINISTRATION; PEPTIC ULCER; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TASTE DISORDER; VERTIGO; VOMITING; ADOLESCENT; ANTIBIOTIC RESISTANCE; DRUG ANTAGONISM; DRUG COMBINATION; DRUG EFFECT; HELICOBACTER INFECTION; MICROBIOLOGY; MIDDLE AGED; PATHOLOGY;

ADOLESCENT; ADULT; AGED; ANTI-BACTERIAL AGENTS; ANTI-INFECTIVE AGENTS, LOCAL; ANTI-ULCER AGENTS; CLARITHROMYCIN; DRUG RESISTANCE, MICROBIAL; DRUG THERAPY, COMBINATION; FEMALE; FURAZOLIDONE; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; MALE; MIDDLE AGED; ORGANOMETALLIC COMPOUNDS; PEPTIC ULCER; PROTON PUMPS;

EID: 0032587348     PISSN: 02692813     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2036.1999.00487.x     Document Type: Article

References (23)

1. 1 NIH Consensus Development Panel. Helicobacter pylori in peptic ulcer disease. J Am Med Assoc 1994; 272: 65-9.
2. 2 The European Helicobacter pylori Study Group. Current European concepts in management of Helicobacter pylori infection. The Maastricht Consensus Report. Gut 1997; 41: 8-13.
3. 3 Lam SK, Talley NJ. Report of the 1997 Asia Pacific consensus conference on the management of Helicobacter pylori infection. J Gastroenterol Hepatol 1998; 13: 1-12
4. 4 Van der Hulst RWM, Keller JJ, Rauws EA, Tytgat GNJ. Treatment of Helicobacter pylori infection: a review of the world literature. Helicobacter 1996; 1: 138-44.
5. 5 Walsh JH, Peterson WL. The treatment of Helicobacter pylori infection in the management of peptic ulcer disease. N Engl J Med 1995; 333: 984-91.
6. 6 Xia HX, Buckley M, Hyde D, keane CT, O'Morain CA. Effects of antibiotic-resistance on clarithromycin-combined triple therapy for Helicobacter pylori. Gut 1995; 37(Suppl.): A55(Abstract).
7. 7 Noach LA, Langenberg WL, Bertola MA, Dankert J, Tytgat GNJ. Impact of metronidazole resistance on the eradication of Helicobacter pylori. Scand J Infect Dis 1994; 26: 321-7.
8. 8 Reddy R, Osato M, Gutierrez O, Kim JG, Graham DY. Metronidazole resistance is high in Korea and Colombia and appears to be rapidly increasing in the US. Gastroenterology 1996; 110: A 238.
9. 9 SeBoer WAD, Tytgat GNJ. The best therapy for Helicobacter pylori infection: Should efficacy or side-effect profile determine our choice. Scand J Gastroenterol 1995; 30: 401-7.
10. 10 Segura AM, Gutierrez O, Otero W, Angel A, Genta RM, Graham DY. Furazolidone, amoxycillin, bismuth triple therapy for Helicobacter pylori infection. Aliment Pharmacol Ther 1997; 11: 529-32.
11. 11 Morgan D, Kraft W, Bender M, Pearson A. Nitrofurans in the treatment of gastritis associated with Campylobacter pylori. The Gastrointestinal Physiology Working Group of Cayetano Heredia and The Johns Hopkins Universities. Gastroenterology 1988; 95: 1178-84.
12. 12 Graham DY, Kleim PD, Opekum AR, et al. In vivo susceptibility of Campylobacter pylori. Am J Gastroenterol 1989; 84: 233-8.
13. 13 Xiao SD, Liu WZ, Xia DH, et al. The efficacy of furazolidone and metronidazole in the treatment of chronic gastritis associated with Helicobacter pylori - a randomized double-blind placebo-controlled clinic trial. HepatoGastroenterology 1990; 37: 503-6.
14. 14 Xiao SD, Liu WZ, Lin GJ, et al. TDB combined therapy for eradication of Helicobacter pylori. Chinese J Digestion 1995; 15(Suppl.): 16-18.
15. 15 Haas CE, Nix DE, Schentag JJ. In vitro selection of resistant Helicobacter pylori. Antimicrob Agents Chemother 1990; 34: 1737-41.
16. 16 Zheng ZT, Wang ZY, Chu YX, et al. Double-blind short term trial of furazolidone in peptic ulcer. Lancet 1985; i: 1048-9.
17. 17 Zheng ZT, Wang YB. Treatment of peptic ulcer disease with furazolidone. J Gastroenterol Hepatol 1992; 7: 533-7.
18. 18 Peterson WL, Graham DY, Marshall B, et al. Clarithromycin as monotherapy for eradication of Helicobacter pylori: a randomized double-blind trial. Am J Gastroenterol 1993; 88: 1860-4.
19. 19 Pipkin GA, Dixon JS, Williamson R, Wood JR. Clarithromycin dual therapy regimens for eradication of Helicobacter pylori: a review. Helicobacter 1997; 2: 159-71.
20. 20 de Boer WA, Tytgat GNJ. 90% cure: which anti-Helicobacter pylori therapy can achieve this treatment goal? Am J Gastroenterol 1995; 90: 1381-2.
21. 21 Liu WZ, Li BM, Xiao SD, et al. Clarithromycin combined short-term triple therapies for eradication of H. pylori. Chinese J Int Med 1996; 35: 803-6.
22. 22 Labenz J, Stolte M, Blum AL, et al. Intragastric acidity as a predictor of the success of Helicobacter pylori eradication: a study in peptic ulcer patients with omeprazole and amoxycillin. Gut 1995; 37: 39-45.
23. 23 Michlke S, Mannes GA, Lehn N, et al. An increasing dose of omeprazole combined with amoxycillin cures Helicobacter pylori infection more effectively. Aliment Pharmacol Ther 1997; 11: 323-9.